Abstract |
Clinical investigations of ITCL drug ("Polfa") were carried out on 50 patients (15 women, 16 men, 19 children, at the age of 4-80). ITCL has been successful in non-specific inflammations accompanying some virus dermatoses ( zoster, herpes simplex), in streptococcal pyoderma ( impetigo, ecthyma), and in some allergic dermatoses (disseminated eczema and atopic dermatitis). Encouraging results were obtained with ITCL in the treatment of psoriasis. It seems that the further attempts with this should be continued in psoriasis. The capillaroscopic examinations in 6 patients revealed ITCL to have vasoconstrictive effect on the nail wall cutis capillaries 6 h after its application. This may be associated with the anti-inflammatory effect of the drug.
|
Authors | R Michałowski, Z Olejnicka, S Kozak, J Urban |
Journal | Archivum immunologiae et therapiae experimentalis
(Arch Immunol Ther Exp (Warsz))
Vol. 31
Issue 5
Pg. 649-54
( 1983)
ISSN: 0004-069X [Print] Switzerland |
PMID | 6675572
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Thiazoles
- 5-(benzoylamino)-N-(4-chlorophenyl)-3-methyl-4-isothiazolecarboxamide
|
Topics |
- Administration, Topical
- Adolescent
- Adult
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Child
- Child, Preschool
- Dermatitis, Atopic
(drug therapy)
- Female
- Herpes Simplex
(drug therapy)
- Herpes Zoster
(drug therapy)
- Humans
- Male
- Middle Aged
- Molluscum Contagiosum
(drug therapy)
- Psoriasis
(drug therapy)
- Pyoderma
(drug therapy)
- Skin Diseases
(drug therapy)
- Skin Diseases, Infectious
(drug therapy)
- Thiazoles
(pharmacology)
- Warts
(drug therapy)
|